Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The discovery that the mitochondrial genome encodes biologically active peptides — beyond the 13 long-recognized subunits of the electron transport chain — has reshaped a core area of cellular biology. Mitochondrial-derived peptides (MDPs) research has emerged as one of the most rapidly developing fields in mitochondrial science, with researchers identifying a growing family of short, bioactive sequences encoded within small open reading frames (sORFs) of mitochondrial DNA. These molecules function not only as local signals within the organelle of origin but as systemic, endocrine-like factors with effects on energy metabolism, stress resistance, and cellular aging.
The MDP field was opened by the 2003 identification of humanin, a 24-amino-acid peptide encoded within the 16S rRNA region of mitochondrial DNA, by Yuichi Hashimoto and Ikuo Nishimoto [1]. More than a decade later, in 2015, Changhan Lee, Pinchas Cohen, and colleagues described MOTS-c — Mitochondrial Open Reading Frame of the Twelve S rRNA-c — a 16-amino-acid peptide with prominent metabolic activity [2]. Their work, and subsequent in silico screening of mitochondrial sORFs, expanded the family to include SHLP1 through SHLP6 (small humanin-like peptides) [3]. Alongside these naturally occurring MDPs, the synthetic SS-31 tetrapeptide developed by Hazel Szeto and Peter Schiller represents a closely related research class: mitochondrial-targeted peptides designed to selectively localize to the inner mitochondrial membrane [4].
This article provides a structured overview of the mitochondrial-derived peptides research class — the biology behind each member, key mechanistic findings, and the experimental contexts in which they are most commonly studied.
Peptide Class Overview
The MDP class is defined by a shared origin: each peptide is encoded by a small open reading frame within the circular mitochondrial genome rather than by nuclear DNA. Humanin and the SHLPs map to MT-RNR2 (the 16S mitochondrial ribosomal RNA gene). MOTS-c maps to MT-RNR1 (the 12S mitochondrial ribosomal RNA gene). Each MDP is relatively short — typically 16 to 38 amino acids — facilitating chemical synthesis for research applications.
SS-31 (D-Arg-2′6′-Dmt-Lys-Phe-NH₂) does not arise from the mitochondrial genome; rather, it is a synthetic cell-penetrating tetrapeptide engineered to selectively bind cardiolipin on the inner mitochondrial membrane. Because of this functional alignment with the MDP class — both groups exert their effects through mitochondrial biology — researchers commonly study SS-31 alongside the endogenous MDPs as part of the broader mitochondrial peptide research landscape [4].
Shared Mechanisms and Research Context
While each MDP has its own distinct mechanism, several themes recur across the class. AMPK activation, modulation of mitochondrial bioenergetics, regulation of apoptotic pathways, and influence on metabolic gene expression appear in studies of multiple MDPs. Researchers commonly examine these compounds in models of metabolic stress, neurodegeneration, age-related decline, ischemia-reperfusion injury, and mitochondrial disease. The class as a whole represents a probe for studying mitochondrial-nuclear communication.
Key Research Areas
1. MOTS-c — Metabolic Regulation and Exercise Biology
MOTS-c is the most studied MDP after humanin. Lee et al. (2015) demonstrated that MOTS-c administration reduced obesity, improved insulin sensitivity, and activated AMPK signaling in mouse models of high-fat-diet–induced metabolic dysfunction [2]. Subsequent research by Kim et al. (2018) showed that under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus, where it regulates expression of nuclear genes involved in antioxidant defense and metabolic homeostasis [5]. A 2021 study by Reynolds et al., published in Nature Communications, characterized MOTS-c as an exercise-induced regulator of age-dependent physical decline and skeletal muscle homeostasis, finding that late-life MOTS-c administration in mice improved physical capacity [6]. Research-grade MOTS-c is widely used in studies of mitochondrial signaling, sarcopenia models, and metabolic disease research.
Ramanjaneya M., Bettahi I., Jerobin J., Chandra P., Abi Khalil C., Skarulis M., Atkin S.L., Abou-Samra A.B. (2019), publishing in Frontiers in Endocrinology, characterized circulating MOTS-c levels across multiple metabolic states and ages in human and rodent cohorts, providing observational context for the experimental supplementation literature. Lu H., Tang S., Xue C., Liu Y., Wang J., Zhang W., Luo W., Chen J. (2019) reported MOTS-c effects on cardiac ischemia-reperfusion injury in rat models, extending the MOTS-c literature beyond purely metabolic endpoints to include cardioprotection through AMPK-dependent pathways.
2. Humanin — Neuroprotection and Stress Resistance
Humanin was first identified through a screen for factors protecting neurons from amyloid-beta toxicity in models of Alzheimer’s disease [1]. Subsequent research demonstrated that humanin interacts with the pro-apoptotic Bcl-2 family member Bax, sequestering it and preventing mitochondrial outer membrane permeabilization. Lee et al. (2013) reviewed humanin’s emerging role in stress resistance, characterizing its anti-apoptotic actions across multiple cell types and its potential role in age-related disease research [7]. Humanin and its synthetic analog HumaninS14G have been studied in preclinical models of cerebral ischemia, ALS, and metabolic dysfunction.
The receptor pharmacology of humanin includes a heterotrimeric cell-surface complex comprising CNTFR, WSX-1, and gp130 that activates STAT3 signaling, alongside the direct cytosolic interaction with BAX characterized by Guo B., Zhai D., Cabezas E., et al. (2003) in Nature. Hashimoto Y., Niikura T., Tajima H., et al. (2001) provided the original report of humanin as a rescue factor for amyloid-β-induced and familial Alzheimer’s disease-gene-induced neuronal cell death.
3. SHLPs (Small Humanin-Like Peptides 1–6) — Differential Bioactivity
The SHLP family was characterized by Cobb et al. (2016) in the Cohen laboratory through in silico screening of mitochondrial sORFs [3]. The six SHLPs (ranging from 20 to 38 amino acids) display distinct and overlapping bioactivities: SHLP2 and SHLP3 demonstrate cytoprotective and insulin-sensitizing effects in preclinical models, while SHLP6 has been associated with the opposite, pro-apoptotic profile. Mehta et al. (2019) reported that humanin and SHLP2 treatment in diet-induced obese mice produced distinct metabolomic signatures, supporting the concept that MDPs act as a coordinated peptide signaling network [8].
The biological diversity within the SHLP family — with members ranging from cytoprotective to pro-apoptotic phenotypes — provides a tractable framework for structure-activity investigation within a tightly related sequence family. Yen K., Wan J., Mehta H.H., Miller B., Christensen A., Levine M.E., Salomon M.P., Brandhorst S., Xiao J., Kim S.J., Navarrete G., Campo D., Harry G.J., Longo V., Pike C.J., Mack W.J., Hodis H.N., Crimmins E.M., Cohen P. (2018) extended the SHLP literature with measurements of SHLP2 in human and rodent cohorts, reporting age-dependent declines in circulating peptide levels that parallel those observed for humanin.
4. SS-31 — Mitochondrial-Targeted Cardiolipin Binding
SS-31 was developed by Szeto and colleagues at Cornell as a member of a series of cell-penetrating peptides designed to selectively accumulate in the inner mitochondrial membrane. Birk et al. (2013) characterized SS-31 as a first-in-class cardiolipin-protective compound, demonstrating that it binds selectively to cardiolipin via electrostatic and hydrophobic interactions and preserves cristae architecture under conditions of oxidative stress [4]. Mitchell et al. (2020) used quantitative proteomics to map the mitochondrial protein interaction landscape of SS-31, confirming its preferential engagement with cardiolipin-binding proteins of the electron transport chain [9]. SS-31 has been studied in preclinical models of cardiac ischemia, kidney disease, and rare mitochondrial disorders such as Barth syndrome.
Szeto H.H. (2014), publishing in British Journal of Pharmacology, provided a comprehensive review of the Szeto-Schiller (SS) peptide series mechanism of action, with particular emphasis on the structural features that drive selective accumulation at the inner mitochondrial membrane and the cardiolipin-binding interface. Siegel M.P., Kruse S.E., Percival J.M., Goh J., White C.C., Hopkins H.C., Kavanagh T.J., Szeto H.H., Rabinovitch P.S., Marcinek D.J. (2013) examined SS-31’s effects on age-associated mitochondrial dysfunction in skeletal muscle, reporting improvements in oxidative phosphorylation efficiency and exercise capacity in aged mice.
Comparative Research Landscape
The mitochondrial-derived peptide class and the broader mitochondrial-targeted peptide research landscape together represent one of the most rapidly evolving areas of contemporary peptide science. Situating these compounds against related research peptides clarifies both the distinctive features of the MDP class and its mechanistic neighbors.
Within the broader cytoprotective and aging-related peptide landscape, the MDPs are conceptually adjacent to several other research compound classes. The Khavinson short-peptide bioregulators (including Pinealon, Vilon, and Epitalon) share with the MDPs an interest in aging-related cellular endpoints but engage entirely different proposed mechanisms (direct chromatin interaction vs. receptor-mediated and intracellular signaling). The klotho protein and its peptide fragments represent another aging-related research compound class, with mechanistic emphasis on mineral homeostasis and the FGF23 co-receptor function complementing the metabolic and cytoprotective emphasis of the MDP literature. Within mitochondrial biology specifically, NAD+ and NAD precursor research compounds provide a complementary tool set focused on mitochondrial cofactor availability and sirtuin signaling, while glutathione research compounds address the major endogenous antioxidant system.
SS-31’s distinct position as a synthetic mitochondrial-targeted peptide — rather than a mitochondrial-encoded signaling peptide — provides methodological complementarity to the endogenous MDPs. Where humanin and MOTS-c operate through receptor-mediated and AMPK-dependent signaling at the cellular level, SS-31 functions principally through preservation of inner mitochondrial membrane structure and cardiolipin protection. Investigators studying mitochondrial dysfunction in disease models commonly employ both classes of compound in parallel to dissect the relative contributions of signaling-level vs. structural-level mitochondrial interventions to observed phenotypes.
Research Methodology Considerations
Investigators planning mitochondrial peptide research should consider several methodology-specific factors that span the MDP and mitochondrial-targeted peptide classes. The first major consideration is the choice between cell-culture and in vivo experimental systems, and within in vivo systems the route of administration. Most MDPs and SS-31 have been studied via systemic (intraperitoneal, subcutaneous) administration in rodents, with continuous infusion using osmotic minipumps employed for chronic exposure studies. Pharmacokinetic characterization for individual MDPs remains limited compared to small-molecule drugs, and investigators should consult primary literature for specific protocols matched to their experimental system.
For cellular assays, common readouts include mitochondrial membrane potential (assessed by TMRM, JC-1, or Rhodamine 123 fluorescence), ATP production rates (luciferin-luciferase or Seahorse extracellular flux analysis), reactive oxygen species generation (MitoSOX, DCFDA), and apoptotic markers (caspase-3 activation, cytochrome c release, annexin V/PI flow cytometry). For MOTS-c and AMPK-related research, phospho-AMPK and downstream phospho-ACC immunoblotting provide direct readouts of pathway activation. For humanin BAX-binding research, in vitro reconstitution assays using purified BAX and isolated mitochondria provide the most mechanistically clean experimental system.
Animal models commonly employed in mitochondrial peptide research include high-fat-diet-induced obesity and insulin resistance (for MOTS-c metabolic studies), aged rodents (typically 18-24 months for late-life MDP supplementation), cardiac ischemia-reperfusion models (commonly employed for SS-31 cardioprotection studies), kidney ischemia-reperfusion models (also frequently used for SS-31), and various models of neurodegeneration including amyloid-β intracerebroventricular infusion and transgenic AD models (commonly used for humanin neuroprotection studies). Selection of the appropriate model should be matched to the specific research question and the mechanistic literature for the peptide under study.
Common methodological pitfalls in mitochondrial peptide research include the assumption that systemically administered peptides reach mitochondrial sites of action at biologically relevant concentrations (often requiring direct verification by mass spectrometric or radiolabel tracking); the failure to distinguish primary mitochondrial effects from secondary consequences of cellular cytoprotection; and the use of acute single-dose endpoints to interpret what are often chronic, slowly developing mitochondrial adaptations. Investigators should consider time-course experiments, parallel measurements of upstream and downstream pathway markers, and orthogonal validation across multiple cell or tissue systems to anchor mechanistic conclusions.
Research Considerations for Laboratory Use
Mitochondrial-derived peptides are supplied as lyophilized powders and typically stored at −20°C for long-term archiving and 2–8°C for short-term use after reconstitution. Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution solvent for most MDPs at neutral pH, though peptides containing methionine residues (such as humanin’s M5 position) may benefit from solvent systems that minimize oxidation. Research-grade material should be obtained at ≥98% HPLC purity with a current Certificate of Analysis. Reconstituted solutions should be aliquoted to minimize freeze-thaw cycles and characterized by analytical HPLC where dose accuracy is critical to the experimental design.
Conclusion
The mitochondrial-derived peptides research class — anchored by humanin, MOTS-c, the SHLPs, and the mitochondrial-targeted SS-31 — represents a young but rapidly expanding area of preclinical investigation. These molecules have introduced a new conceptual framework: that mitochondria function not only as organelles of energy metabolism but as endocrine-like signaling centers communicating with the nucleus and across cells. The collective MDP literature spans cellular bioenergetics, metabolic regulation, neuroprotection, and aging research, providing a rich set of tools for laboratory studies of mitochondrial biology and intercellular signaling.
As with all peptide research, MDP studies remain firmly in the preclinical domain. Continued mechanistic work — particularly identification of definitive receptors and characterization of pharmacokinetic profiles — will shape the next phase of MDP biology.
Frequently Asked Questions
What are mitochondrial-derived peptides?
Mitochondrial-derived peptides (MDPs) are short bioactive peptides encoded within small open reading frames of the mitochondrial genome. Members include humanin, MOTS-c, and SHLP1–6. They function as both intracellular signals and circulating endocrine-like factors with effects on metabolism, stress resistance, and cellular aging biology.
How does SS-31 differ from the endogenous MDPs?
SS-31 is a synthetic cell-penetrating tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane, while humanin, MOTS-c, and the SHLPs are encoded by mitochondrial DNA. SS-31 is grouped with the MDPs in research contexts because its activity is also mediated through mitochondrial biology — specifically, the preservation of mitochondrial membrane structure and function.
What research models are used for mitochondrial-derived peptide studies?
Common research models include cultured mammalian cell lines (especially myocytes, neurons, hepatocytes, and pancreatic beta cells), aged mouse models (e.g., for MOTS-c exercise and aging studies), high-fat-diet–induced metabolic models, ischemia-reperfusion injury models for SS-31, and amyloid toxicity models for humanin neuroprotection research.
What is the purity standard for research-grade mitochondrial peptides?
Research-grade MDPs should meet ≥98% purity by HPLC analysis with mass spectrometry confirmation of identity. Each lot should be accompanied by a Certificate of Analysis documenting purity, sequence verification, water content, and counterion identity.
How were the mitochondrial-derived peptides discovered?
Humanin was identified in 2001 through a functional expression screen of cDNA libraries from postmortem Alzheimer’s disease brain tissue, by Hashimoto and colleagues at Keio University. MOTS-c was identified in 2015 by Lee and Cohen at USC through bioinformatic analysis of small open reading frames within the mitochondrial 12S ribosomal RNA gene, followed by synthesis and bioactivity confirmation. The SHLP peptides were subsequently identified by Cobb and colleagues in the Cohen laboratory through systematic in silico screening of additional mitochondrial open reading frames.
What is the relationship between MOTS-c and AMPK?
MOTS-c is a potent activator of AMP-activated protein kinase (AMPK), a central energy-sensing kinase that integrates cellular metabolic state. AMPK activation by MOTS-c has been reported to occur through modulation of folate-methionine cycle metabolism, with downstream effects on glucose uptake, fatty acid oxidation, and exercise-mimetic gene expression programs. The MOTS-c/AMPK axis has been proposed as a mechanistic basis for the peptide’s metabolic and exercise-related effects in preclinical models.
What is cardiolipin and why does SS-31 target it?
Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it is essential for the proper organization and function of the electron transport chain. Oxidative damage to cardiolipin during conditions of mitochondrial stress is associated with impaired bioenergetics and increased apoptotic signaling. SS-31 binds cardiolipin via electrostatic and hydrophobic interactions, preserving cristae architecture and supporting electron transport chain function under stress conditions.
Are SHLP peptides as well-characterized as humanin and MOTS-c?
No — the SHLP family is the youngest member of the MDP class, having been characterized in detail only since 2016. While each of the six SHLPs has been shown to display measurable bioactivity in cellular assays, the depth of mechanistic characterization, receptor pharmacology, and in vivo investigation remains substantially less than for humanin or MOTS-c. The SHLPs represent an active area of investigation with substantial room for additional mechanistic and translational work.
What are common in vivo models used in mitochondrial peptide research?
Standard in vivo models include high-fat-diet-induced obesity and insulin resistance models (for MOTS-c metabolic studies), aged rodents (typically 18-24 months for late-life MDP supplementation), cardiac and renal ischemia-reperfusion models (frequently used for SS-31 studies), amyloid-β intracerebroventricular infusion and transgenic Alzheimer’s models (for humanin neuroprotection research), and various mitochondrial disease models for general mitochondrial peptide investigation.
References
- Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98(11):6336–6341. PMID: 11371646.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459.
- Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796–809. PMID: 27070352.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261. PMID: 24117165.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516–524. PMID: 29983246.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109.
- Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24(5):222–228. PMID: 23402768.
- Mehta HH, Xiao J, Ramirez R, et al. Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment. Metabolomics. 2019;15(6):88. PMID: 31172328.
- Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363–15373. PMID: 32554501.
- Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne). 2019;10:331. PMID: 31231308.
- Yen K, Wan J, Mehta HH, et al. Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Sci Rep. 2018;8(1):14212. PMID: 30242290.
- Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456-461. PMID: 12732850.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. PMID: 24117165.
- Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763-771. PMID: 23692570.
